Navigation Links
NeoTract Designates Dr. Elizabeth Mobley as UroLift® Center of Excellence
Date:5/23/2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Elizabeth Mobley, MD, Urology Austin in Austin, TX, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Elizabeth Mobley has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Elizabeth Mobley has earned the UroLift Center of Excellence designation for her dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #
For Teleflex Incorporated:
Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations
Media:
Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction
1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Read the full story at https://www.prweb.com/releases/neotract_designates_dr_elizabeth_mobley_as_urolift_center_of_excellence/prweb16333224.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. NeoTract Designates Dr. Kalpesh Patel as UroLift® Center of Excellence
2. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
3. Caris Life Sciences Designates MedStar Health a Caris Center of Excellence
4. Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence
5. Caris Life Sciences Designates Fox Chase Cancer Center a Caris Center of Excellence in Precision Medicine
6. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
7. La doctora Elizabeth H. Blackburn, Premio Nobel, se une al panel del ASTELLAS INNOVATION DEBATE 2013
8. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
9. Final Results of Veinviewer Utilization Study at St. Elizabeth Healthcare Show Potential Savings of More Than $238,000 in 2013
10. Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore
11. CME Group Announces Elizabeth Holmes as the 2015 Melamed-Arditti Innovation Award Recipient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2019)... ... , ... The latest edition of Crystallography Times from Rigaku ... , Crystallography Times is a monthly electronic newsletter published by Rigaku focusing on ... latest news and crystallographic research. , “Crystallography in the News” is a monthly ...
(Date:8/21/2019)... ... August 21, 2019 , ... ... to enhance cybersecurity workforce education and training. To commence the partnership, Purdue University ... cybersecurity practitioners. Businesses in the United States now have the opportunity to work ...
(Date:8/19/2019)... ... ... many senior executives in complex industries, a former Procter & Gamble Vice President learned that ... it. He turned a make-it-or-break-it opportunity — debating his company’s biggest critic on live ... , On Monday, September 9, 2019 at 12pm EDT (5pm BST/UK), join 3D Executive ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... August 16, 2019 , ... The clinical trial supply chain ... to change. , Join Just In Time Manufacturing Solutions Manager at Almac ... 11, 2019 at 11am EDT (4pm BST/UK) on a journey through time as it ...
(Date:8/16/2019)... ... August 16, 2019 , ... Tim Stouffer, ICS ... Mid-Atlantic and North East at the 2019 Safety Academy sponsored through Associated Builders ... existing construction safety concepts and define not only a safety program but focus ...
(Date:8/15/2019)... ... August 15, 2019 , ... Inc. ... Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. ... American economy’s most dynamic segment—its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, ...
(Date:8/15/2019)... ... ... either starting college for the first time, and returning to school, the number of STIs ... are about 20 million new cases of STDs each year in the United States. About ... people are at greater risk of getting an STD.” To that end, myLAB Box ...
(Date:8/15/2019)... ... August 15, 2019 , ... Heritage Woods of Rockford Administrator ... Assisted Living (NCAL). , This award is part of the NCAL Awards Program, which ... , “The common element among this year’s recipients is that they all go out ...
Breaking Medicine News(10 mins):